EUS-RFA PANCARDINAL-1 Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe University of Texas Health Science Center, Houston
About this trial
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
Eligibility criteria
Qualifiers
Diagnosed and histologically-confirmed PDAC by biopsy
Permanent street address
Consent to study participation
Axial CT scan consistent with PDAC
Disqualifiers
Male or female patients < 18 years of age
No permanent street address or telephone number
Pregnant patients
Inmates or prisoners
Trial design
Treatments tested in this trial
- Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)
- Neoadjuvant Chemotherapy (NAC)
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
The University of Texas Health Science Center, Houston
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov